Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.

AJNR. American journal of neuroradiology·2020
Same author

Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules.

European journal of neurology·2020
Same author

Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis.

European journal of neurology·2019
Same author

Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up.

European journal of neurology·2019
Same author

Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.

AJNR. American journal of neuroradiology·2019
Same author

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

AJNR. American journal of neuroradiology·2018
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Prescribing recommendations for interferon-Beta in multiple sclerosis.

B Weinstock-Guttman1, R A Rudick

  • 1The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, Ohio, 44195, USA, guttmab@cesmtp.ccf.org.

CNS Drugs
|January 23, 2013
PubMed
Summary
This summary is machine-generated.

Interferon beta (IFNβ) is the first FDA-approved treatment to modify multiple sclerosis (MS) disease course. While effective, long-term benefits, toxicity, and cost require further study for optimal patient selection and management.

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Experiment Videos

Last Updated: May 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Area of Science:

  • Neuroimmunology
  • Autoimmune Diseases

Background:

  • Multiple sclerosis (MS) is a leading cause of disability in young adults.
  • Current MS treatment strategies focus on immunosuppression and immunomodulation.
  • Interferons (IFNs) are utilized for their immunoregulatory effects in MS therapy.

Purpose of the Study:

  • To review the efficacy and practical considerations of Interferon beta (IFNβ) in treating multiple sclerosis (MS).
  • To discuss the approval and different forms of IFNβ used for MS.
  • To highlight areas needing further investigation regarding long-term outcomes and patient management.

Main Methods:

  • Review of two Phase III randomized, placebo-controlled clinical trials for IFNβ efficacy.
  • Analysis of FDA approval and global market status of IFNβ-1b and IFNβ-1a.
  • Discussion of clinical practice issues including long-term benefits, toxicity, cost, and patient selection.

Main Results:

  • IFNβ-1b and IFNβ-1a are approved for relapsing-remitting MS based on clinical and MRI trial data.
  • IFNβ-1b is produced in E. coli, while IFNβ-1a is produced in mammalian cells, with distinct characteristics.
  • IFNβ is the first FDA-approved therapy to alter the natural course of MS.

Conclusions:

  • Despite demonstrated efficacy, long-term benefits and toxicities of IFNβ therapy remain largely undefined.
  • High therapy costs necessitate careful patient selection based on disease type and progression likelihood.
  • Effective patient education, support, and periodic neurological reassessment are crucial for managing chronic IFNβ therapy.